Show Summary Details
Page of

Adjuvant therapy for head and neck malignancy 

Adjuvant therapy for head and neck malignancy
Adjuvant therapy for head and neck malignancy

Charles G. Kelly

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 24 November 2020

The non-surgical management of oral and oropharyngeal (OMF) tumours and head and neck cancer in general has changed over the last decade, with the development of new radiotherapy technology and techniques. Novel chemotherapy drugs, chemotherapy regimens, and the use of biological agents have also been introduced. These changes have altered the patterns of morbidity and side effects of non-surgical treatments both in the acute treatment phase and with long-term effects but most importantly has been the overall change in approach to the management of head and neck cancer, with much greater emphasis on organ preservation and post-treatment function. Presurgical adjuvant therapy is becoming increasingly common in the management of malignancy. This chapter describes the radio- and chemotherapeutic treatments for oral and maxillofacial malignancy and the consequences that are of most interest to the anaesthetist.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.